INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,481,000 | -43.1% | 59,970 | -4.6% | 0.00% | -50.0% |
| Q3 2020 | $2,605,000 | -19.0% | 62,843 | -6.4% | 0.00% | -33.3% |
| Q2 2020 | $3,215,000 | -24.1% | 67,111 | -0.2% | 0.00% | -40.0% |
| Q1 2020 | $4,235,000 | -54.6% | 67,258 | -10.6% | 0.01% | -44.4% |
| Q4 2019 | $9,321,000 | +74.3% | 75,216 | -6.7% | 0.01% | +50.0% |
| Q3 2019 | $5,349,000 | -16.1% | 80,602 | +0.6% | 0.01% | -14.3% |
| Q2 2019 | $6,374,000 | -21.1% | 80,109 | +5.4% | 0.01% | +40.0% |
| Q1 2019 | $8,078,000 | +111.1% | 75,974 | +100.1% | 0.01% | 0.0% |
| Q4 2018 | $3,826,000 | -21.3% | 37,964 | -1.3% | 0.01% | -16.7% |
| Q3 2018 | $4,862,000 | +30.0% | 38,475 | -13.7% | 0.01% | +20.0% |
| Q2 2018 | $3,741,000 | +52.9% | 44,587 | +12.2% | 0.01% | +66.7% |
| Q1 2018 | $2,446,000 | +5.1% | 39,752 | -0.3% | 0.00% | 0.0% |
| Q4 2017 | $2,328,000 | +198.5% | 39,852 | +196.6% | 0.00% | +200.0% |
| Q3 2017 | $780,000 | – | 13,436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |